Type
Internal restructuring
Country
Austria
Region
Ostösterreich; Niederösterreich; Wiener Umland/Nordteil
Location of affected unit(s)
Orth an der Donau
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture Of Pharmaceutical Preparations

190 jobs
Number of planned job losses
Job loss
Announcement Date
29 February 2024
Employment effect (start)
29 February 2024
Foreseen end date

Description

Takeda, a Japanese pharmaceutical company, operates in Orth an der Donau, Lower Austria, with a focus on gene therapy products.The company has decided to sell most of this facility, impacting 190 of 330 employees.

This change stems from Takeda's global decision to discontinue research and preclinical activities in gene therapy using adeno-associated viruses (AAV), which was a key capability of the Orth site.

Takeda has pledged support for affected staff, offering counselling and job placement assistance.This decision, communicated internally in April 2023, did not affect Takeda's other Austrian sites in Vienna and Linz, where it employs over 4,500 staff.


Sources

Citation

Eurofound (2024), Takeda, Internal restructuring in Austria, factsheet number 202211, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/202211.